This year marks a turning point in Alzheimer's research.
What was once a disease diagnosed after symptoms appeared is increasingly becoming one that researchers hope to detect earlier, intervene against from multiple angles, and perhaps someday prevent altogether. While there is still no cure for Alzheimer's disease, meaningful progress is being made across the spectrum — from prevention science to treatment.
As part of Alzheimer's and Brain Awareness Month 2026, we're highlighting some of the most exciting developments in brain health research. In this article, we'll explore three areas generating significant attention among scientists and clinicians: blood-based biomarkers, GLP-1 medications, and a major shift in how Alzheimer's treatments are being developed.
Blood-Based Biomarkers: What If a Blood Test Could Predict Alzheimer's?
The idea of predicting your future brain health with a simple blood test may sound unsettling. Researchers, however, see it as something far more empowering.
For people already on the path toward Alzheimer's disease, earlier detection could mean earlier treatment and a greater opportunity to slow progression. For those who have not yet developed symptoms, it could create a valuable window for prevention — one that may not have existed before.
Recent findings from the U.S. POINTER study reinforced the powerful role lifestyle interventions play in supporting brain health and reducing risk. Blood-based biomarkers could help identify who might benefit most from those interventions and when they should begin.
For decades, clinicians have relied on measures like A1C to assess metabolic health and diabetes risk. Researchers have long hoped for something similar in Alzheimer's disease: a tool that could reveal biological changes before significant symptoms appear.
Blood-based biomarkers may provide that opportunity.
These tests measure proteins in the blood that reflect changes occurring in the brain. Two of the most important are p-tau217 and amyloid beta 42 (Aβ42). Amyloid beta 42 is associated with the buildup of amyloid plaques in the brain, while p-tau217 reflects these amyloid plaques and also the formation of tau tangles — two hallmark features of Alzheimer's disease.
What makes p-tau217 particularly exciting is how early it appears. Research suggests levels can begin rising 15 to 20 years before memory symptoms develop.1 It has also emerged as one of the most accurate blood-based markers currently available, closely tracking Alzheimer's-related brain changes and future cognitive decline.
They also offer practical advantages. Until recently, confirming Alzheimer's-related changes often required expensive PET brain scans or invasive spinal taps (thousands of dollars). Blood tests are far less costly (hundreds of dollars), more accessible, and easier to incorporate into routine clinical care.
In fact, this technology is already beginning to change clinical care. In 2025, the first FDA-cleared blood-based biomarker test entered clinical use, marking a major milestone in Alzheimer's diagnosis, and the impact has been immediate.
Read our coverage of this development in our previous article, Highlights from AAIC 2025: Cutting Edge Findings in Brain Health and Alzheimer’s Disease.
Jeffrey Cummings, M.D., Sc.D., a NeuroReserve Medical Advisor, participated in a 2025 implementation study at the Cleveland Clinic Lou Ruvo Center for Brain Health. After introducing plasma p-tau217 testing into the clinic's workflow, the average time required to reach a biological diagnosis dropped from 11 weeks to just 9 days. The need for spinal fluid testing fell by 67%, and the use of amyloid PET scans dropped by 54%, while maintaining diagnostic accuracy.2
For patients, that means faster answers, fewer invasive procedures, and quicker access to appropriate care.
A Biological Clock: Predicting Alzheimer's Before Symptoms Begin
As impressive as these diagnostic advances are, the greatest excitement may lie in what blood-based biomarkers could eventually help us predict.
A groundbreaking 2026 study published in Nature Medicine found that blood levels of p-tau217 may help estimate how close a person is to developing Alzheimer's symptoms. Researchers described p-tau217 as a potential biological "clock," capable of estimating symptom onset with a margin of error of roughly three to four years.3
Interestingly, the timing appeared to matter. Individuals whose p-tau217 levels became elevated later in life tended to develop symptoms sooner than those whose levels rose at younger ages.3
Another major study, published in The Lancet and led by Kristine Yaffe, M.D., pushed the detection window even earlier. Researchers found that Alzheimer's-related blood biomarkers could already be detected in some cognitively normal adults in their 50s and 60s. Those with positive biomarkers were also significantly more likely to experience accelerated declines in memory and thinking skills over time.4
In other words, Alzheimer's-related changes may be affecting brain function years before symptoms become obvious.
As Yaffe noted, "Testing could open a window to embark on interventions that may postpone Alzheimer's onset."
That possibility represents a fundamental shift in thinking. Instead of waiting for symptoms to emerge, clinicians may eventually be able to identify biological changes years — or even decades — earlier and help people take action while there is still time to influence their trajectory.
That opportunity is especially important given estimates from the Lancet Commission suggesting that approximately 40% of dementia cases may be preventable through modification of known risk factors.5
For the first time, researchers can begin to envision a future in which Alzheimer's prevention is informed not only by population-level risk factors, but also by personalized biological information from a simple blood test. The sooner people know their status, the more they can do ahead of time to stave off or prevent the disease, and that is a real-life transformation in prevention.
GLP-1 Drugs and Alzheimer's: Why Are Weight-Loss Drugs Being Studied for Brain Health?
Few classes of medications have generated as much attention in recent years as GLP-1 receptor agonists (e.g. drugs named Ozempic, Mounjaro, Zepbound, and Wegovy). Originally developed to help manage type 2 diabetes, these drugs have become household names because of their effectiveness for weight loss.
Their potential applications are branching out from just diabetes and obesity. Researchers are investigating GLP-1 drugs for cardiovascular disease, chronic kidney disease, fatty liver disease, addiction, and even brain disease — including Alzheimer's.
Be sure to check out our previous article on GLP-1s and brain health.
At first glance, a diabetes medication may seem unrelated to Alzheimer's disease. However, metabolic health and brain health are deeply connected.
People with diabetes face up to a 50% higher risk of developing Alzheimer's disease, and growing evidence suggests that disruptions in glucose regulation, insulin signaling, and energy metabolism may contribute to brain aging.6
This idea has helped fuel what researchers call the "metabolic hypothesis" of Alzheimer's disease — the theory that problems involving the brain's ability to produce and use energy may play a role in disease development and progression.
A Year of Big Ups and Downs for GLP-1 Research
Now, researchers are asking how much of a role metabolism plays in this disease. Over the past year, researchers have put that question to the test in some of the largest Alzheimer's clinical trials ever conducted for GLP-1 medications.
The highest-profile results came from the EVOKE and EVOKE+ trials, which evaluated semaglutide (the same drug used in Ozempic) in people with early Alzheimer's disease. The studies involved thousands of participants and represented one of the largest tests yet of the metabolic hypothesis. However, the results reported in late 2025 showed that semaglutide failed to meet its primary endpoint of slowing cognitive decline.7
At nearly the same time, a different GLP-1 medication produced a more encouraging signal. The ELAD trial, which evaluated liraglutide, found evidence of slower brain volume loss and suggested potential benefits for cognitive decline. While the findings were not definitive, they provided enough encouragement to sustain interest in the field.8
Adding another layer of complexity, several observational studies and meta-analyses have reported lower rates of dementia among people taking GLP-1 medications, with some studies suggesting risk reductions of 20% to 35%.9
The mixed results highlight an important reality: the biggest story may not be whether a single GLP-1 drug succeeds or fails.
Instead, these studies are helping researchers better understand the relationship between metabolism and Alzheimer's disease. Questions surrounding brain insulin resistance, energy metabolism, and other metabolic processes are now receiving far more attention than they did just a few years ago.
At this stage, GLP-1 drugs have generated more questions than answers. Yet the vast interest surrounding them reflects something important: Alzheimer's research is expanding beyond traditional theories and exploring a broader range of biological pathways than ever before. And that broader perspective is shaping the future of Alzheimer's treatments.
Alzheimer's Drug Development Is Expanding Beyond Amyloid
For decades, Alzheimer's drug development was dominated by the “amyloid hypothesis” — the idea that preventing or removing amyloid beta plaques from the brain could slow or stop the disease. This theory shaped much of the field's research agenda and led to the first disease-modifying Alzheimer's therapies.
Those treatments remain an important milestone. Recent analyses of anti-amyloid drugs such as lecanemab and donanemab suggest that targeting amyloid can slow disease progression, particularly when treatment begins early.10 But they’ve also made one thing clear: amyloid alone is unlikely to explain the full complexity of Alzheimer’s disease.
A major 2026 analysis led by Jeffrey Cummings, M.D., Sc.D., NeuroReserve Medical Advisor, shows how far the field has moved. With 158 drugs in development and 192 active clinical trials, the Alzheimer’s pipeline is now one of the largest and most diverse in its history.
What’s more revealing than the size of the pipeline is how its focus has changed.
Not long ago, roughly one-third of Alzheimer’s therapies targeted amyloid beta.11 That share has now dropped substantially, signaling a broader shift as researchers expand into other disease pathways. Today, more therapies focus on tau biology and immune or inflammatory processes, with metabolism also emerging as a growing area of interest.
These shifts point to a major change in thinking. Alzheimer’s is increasingly viewed not as a condition driven by a single protein or pathway, but as a multifactorial disease involving amyloid, tau, inflammation, immune dysfunction, metabolism, and other interconnected processes.
As Cummings notes, the current pipeline "provides the basis for optimism regarding the emergence of new therapies for patients with Alzheimer's."
That optimism is progressively tied to a new treatment model. Rather than relying on a single breakthrough drug, the future of Alzheimer’s care may look more like other complex diseases, such as cancer or cardiovascular disease, where combination approaches target multiple biological drivers at once.
Looking Ahead
These developments reveal an Alzheimer's research landscape that looks very different from what it did even a few years ago.
Blood-based biomarkers are making earlier detection possible. GLP-1 research is expanding our understanding of the relationship between metabolism and brain health. Drug developers are pursuing a wider range of biological targets than ever before.
Researchers are no longer approaching Alzheimer's as a single disease driven by a single cause. Instead, they are building a more complete understanding of the many biological factors that contribute to cognitive decline and exploring new ways to detect risk, intervene earlier, and slow progression.
Of all the developments discussed here, blood-based biomarkers may ultimately prove the most transformative to advance prevention strategies. For the first time, researchers can begin to envision a future in which Alzheimer's risk can be detected years before symptoms emerge, creating opportunities to intervene and measure effects that previously did not exist.
That future is still taking shape. And Alzheimer’s research is entering a new era.
Our Mission: Protecting Long-Term Brain Health
At NeuroReserve, our mission is to help protect people from the growing epidemic of neurodegenerative disease and cognitive decline through evidence-based nutrition and dietary guidance.
We offer a range of products inspired by the brain-healthy Mediterranean and MIND dietary patterns, including RELEVATE, our flagship, patented nutritional supplement formulated to support long-term brain health; Brain Health Kitchen Extra Virgin Olive Oil, a staple of evidence-backed eating patterns like the Mediterranean and MIND diets; and REVANTA Creatine, designed to support brain energy and cognitive performance.
References:
1. Fu, W. & Ho, P. C.-L. Blood-based biomarkers for Alzheimer’s disease: Advances in early detection and monitoring of age-related neurodegeneration. Ageing Res. Rev. 117, 103058 (2026).
2. The Healthcare Discovery Team. The Alzheimer’s Blood Test Has Arrived: How Plasma p-Tau217 Is Rewriting Early Diagnosis in 2026. Healthcare Discovery AI https://healthcarediscovery.ai/alzheimers-blood-test-ptau217-early-diagnosis-2026/ (2026).
3. Petersen, K. K. et al. Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks. Nat. Med. 32, 1085–1094 (2026).
4. Jiang, X. et al. Alzheimer’s disease neuropathology plasma biomarkers and cognition in midlife: a community-based cohort study. The Lancet 407, 2208–2216 (2026).
5. Livingston, G. et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet 404, 572–628 (2024).
6. Li, L. et al. Increased risk of dementia in Type 1 diabetes: A systematic review with meta-analysis. Diabetes Res. Clin. Pract. 222, 112043 (2025).
7. O’Leary, K. GLP-1 receptor agonist fails to halt Alzheimer’s disease. Nat. Med. https://doi.org/10.1038/d41591-026-00018-2 (2026) doi:10.1038/d41591-026-00018-2.
8. Edison, P. et al. Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial. Nat. Med. 32, 353–361 (2026).
9. Mullins, R. J. et al. A Pilot Study of Exenatide Actions in Alzheimer’s Disease. Curr. Alzheimer Res. 16, 741–752 (2019).
10. van Dyck, C. H. et al. Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine 388, 9–21 (2023).
11. Cummings, J. L. et al. Alzheimer’s disease drug development pipeline: 2026. Alzheimer’s & Dementia: Translational Research & Clinical Interventions 12, (2026).